Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724572 | SCV000233141 | uncertain significance | not provided | 2018-07-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000468202 | SCV000545120 | benign | Intellectual disability, autosomal dominant 1 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724572 | SCV000617113 | benign | not provided | 2019-12-04 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000724572 | SCV001476679 | likely benign | not provided | 2020-04-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000724572 | SCV002063897 | likely benign | not provided | 2024-05-01 | criteria provided, single submitter | clinical testing | MBD5: BS2 |
Ambry Genetics | RCV002354466 | SCV002657145 | likely benign | Inborn genetic diseases | 2022-12-19 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Molecular Genetics Laboratory, |
RCV000678818 | SCV000805004 | uncertain significance | developmental delay with intractable seizures | 2016-11-14 | no assertion criteria provided | clinical testing |